Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 1:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 448 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Treatment of Hepatitis C Clear all
Completed Phase 4 Interventional Results available

PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C.

NCT00087633
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
peginterferon alfa-2a [Pegasys], Copegus
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Phase 2 Interventional

Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications

NCT01455090
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
BMS-650032, BMS-790052, BMS-791325, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
26
States / cities
Birmingham, Alabama • Coronado, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Phase 4 Interventional Results available

Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients

NCT02781649
View directory record Official record
Conditions
End-Stage Renal Disease, Hepatitis C
Interventions
Zepatier, Ribavirin, Sofosbuvir
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Phase 4 Interventional Results available

Multi-center Study to Transplant Hepatitis-C Infected Kidneys

NCT03781726
View directory record Official record
Conditions
Renal Failure Chronic, Hepatitis C
Interventions
glecaprevir/pibrentasvir treatment
Drug
Lead sponsor
Raymond Chung
Other
Eligibility
21 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2022 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Phase 3 Interventional

PEG-Interferon a-2b + Ribavirin for Treatment of Chronic HRN 005 Hepatitis C Infection in HIV-Infected Persons Not Previously Treated With Interferon

NCT00215891
View directory record Official record
Conditions
Chronic Hepatitis C Infection in HIV-Infected Persons, HIV Infections
Interventions
PEG-Interferon a-2b + Ribavirin
Drug
Lead sponsor
Hepatitis Resource Network
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 25, 2005 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Not applicable Interventional

Tool to Improve Treatment Adherence and Outcomes at Grady Liver Clinic

NCT03831555
View directory record Official record
Conditions
Hepatitis C
Interventions
PREP-C
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Not applicable Interventional

Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection

NCT00015652
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Ribavirin, Aldesleukin, Peginterferon alfa-2b
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Phase 2 Interventional Results available

Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis

NCT02226549
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
LDV/SOF, VDV, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Not applicable Interventional Results available

Intensive Models of HCV Care for Injection Drug Users

NCT01857245
View directory record Official record
Conditions
Hepatitis C, Medication Adherence
Interventions
Intensive Models (mDOT and CGT) of HCV Care
Other
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Phase 2 Interventional Results available

Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment

NCT01170962
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
BMS-790052, Placebo, peginterferon alfa-2a, ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
35
States / cities
Montgomery, Alabama • La Jolla, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV Infection

NCT01858766
View directory record Official record
Conditions
Hepatitis C
Interventions
SOF, VEL, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
50
States / cities
La Jolla, California • Long Beach, California • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Phase 3 Interventional

Hepatitis C Antiviral Resistance in African-Americans

NCT00038974
View directory record Official record
Conditions
Hepatitis C
Interventions
peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 70 Years
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
8
States / cities
San Francisco, California • Miami, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Not applicable Interventional Results available

Comparison of Telemedicine to Usual Care for HCV Management for Methadone-maintained Individuals

NCT02933970
View directory record Official record
Conditions
Hepatitis C
Interventions
Telemedicine
Other
Lead sponsor
Andrew Talal
Other
Eligibility
18 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Phase 4 Interventional

Treatment of Acute Hepatitis C Virus Infection With Pegylated Interferon in Injection Drug Users

NCT00194480
View directory record Official record
Conditions
Substance-Related Disorders, Hepatitis
Interventions
Pegylated Interferon
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
15 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment

NCT01183169
View directory record Official record
Conditions
Hepatitis C
Interventions
Alisporivir, Peginterferon alfa-2a, Ribavirin, Placebo
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
18
States / cities
San Diego, California • Ventura, California • Bradenton, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2016 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Phase 2 Interventional

Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone

NCT04710641
View directory record Official record
Conditions
Hepatocellular Carcinoma, Hepatitis B, Hepatitis C
Interventions
MTL-CEBPA, Sorafenib
Drug
Lead sponsor
Mina Alpha Limited
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Phase 4 Interventional Results available

Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection

NCT01097395
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
ribavirin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Phase 2 Interventional

Treatment of Hepatitis C in Hemophilic Patients With HIV

NCT00055341
View directory record Official record
Conditions
HIV Infections, Hepatitis C, Hemophilia
Interventions
Peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
15 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 30, 2008 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Phase 2 Interventional

A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis

NCT01483742
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
RO5024048, danoprevir, peginterferon alfa-2a [Pegasys], ribavirin, ritonavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
15
States / cities
Birmingham, Alabama • Anaheim, California • Coronado, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2016 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Phase 2 Interventional

A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection

NCT02593162
View directory record Official record
Conditions
Hepatitis C Viral Infection, Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 4
Interventions
Faldaprevir, TD-6450, Ribavirin
Drug
Lead sponsor
Trek Therapeutics, PBC
Industry
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Coronado, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Not applicable Interventional Results available

HCV Seek, Test and Rapid Treatment for Young PWID

NCT03627546
View directory record Official record
Conditions
Hepatitis C, Drug Use
Interventions
Rapid Treatment strategy, Usual Care (facilitated referral)
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 29 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Phase 1 Interventional

Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus

NCT00503347
View directory record Official record
Conditions
Hepatitis C Virus, Hiv Infections
Interventions
bavituximab
Drug
Lead sponsor
Peregrine Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
6
States / cities
Los Angeles, California • Newport Beach, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2011 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of the Use of Hepatitis C Positive Donors for Hepatitis C Negative Lung Transplant Recipients With Post-transplant Treatment With Mavyret

NCT03523871
View directory record Official record
Conditions
Hepatitis C
Interventions
Mavyret
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Phase 2 Interventional

Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin

NCT01030432
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
BMS-650032, Placebo, Peginterferon Alfa-2a, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
14
States / cities
Birmingham, Alabama • Montgomery, Alabama • Orlando, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 15, 2026, 1:21 AM EDT